Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Cysteinamide is an amidated derivative of the amino acid cysteine and belongs to the class of alpha amino acid amides. It is a small molecule with the chemical formula C3H8N2OS. Cysteinamide has been studied primarily in experimental and biochemical contexts rather than as an approved pharmaceutical drug. Its most notable biological activity is as an inhibitor of tyrosinase (TYR), a key enzyme in melanin synthesis. By inhibiting tyrosinase and diverting dopaquinone to form DOPA-cysteinamide conjugates instead of dopachrome, it reduces eumelanin production in melanocytes without cytotoxic effects. This property makes it relevant for research into skin pigmentation regulation and potential dermatological applications[6][2]. Additionally, its thiol group confers antioxidant properties and copper chelation ability[6].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Cysteinamide.